DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
AGN-201904 is an investigational drug.
There have been 50 clinical trials for AGN-201904. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2014.
The most common disease conditions in clinical trials are Presbyopia, Ocular Hypertension, and Glaucoma. The leading clinical trial sponsors are Allergan, Naurex, Inc, an affiliate of Allergan plc, and Vitae Pharmaceuticals Inc., an Allergan affiliate.
There are two US patents protecting this investigational drug and forty-three international patents.
Recent Clinical Trials for AGN-201904
|A Study to Assess the Impact and Adverse Events of Topical Eyedrops of AGN-190584 on Night-driving Performance in Participants, 40 to 55 Years of Age||Allergan||Phase 3|
|AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension||Allergan||Phase 1/Phase 2|
|Phase 1/2 Study of AGN-241622 in Healthy Participants and Participants With Presbyopia||Allergan||Phase 1/Phase 2|
Top disease conditions for AGN-201904
Top clinical trial sponsors for AGN-201904
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|AGN-201904||Get Started Free||Prodrugs of proton pump inhibitors||Winston Pharmaceuticals, Inc. (Newport Beach, CA) The United States of America as represented by the Department of Veteran Affairs (Washington, DC) N/A (Oakland, CA) The Reagents of the University of California (N/A)||Get Started Free|
|AGN-201904||Get Started Free||Process for preparing isomerically pure prodrugs of proton pump inhibitors||Allergan, Inc. (Irvine, CA)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|AGN-201904||Argentina||AR042513||2022-07-19||Get Started Free|
|AGN-201904||Austria||AT323695||2022-07-19||Get Started Free|
|AGN-201904||Australia||AU2003259154||2022-07-19||Get Started Free|
|AGN-201904||Brazil||BR0312802||2022-07-19||Get Started Free|
|AGN-201904||Canada||CA2492718||2022-07-19||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|